1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
GC Corp.

GC Corp.

17,000.00
KRW
+270.00
(+1.61%)
Nov 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
934,622
1,043,840
1,132,120
1,354,466
1,464,875
1,547,971
1,493,589
1,719,326
1,840,559
2,079,560
2,057,936
2,204,855
2,451,476
2,487,390
Operating Margin (%)
9.76
10.95
9.44
7.33
7.6
3.14
4.47
4.12
4.69
3.46
-0.8
-0.49
1.49
1.17
Depreciation Expense
20,452
26,045
31,506
35,099
41,244
47,282
56,942
52,831
62,443
78,656
94,846
103,742
107,166
107,715
Net Income, GAAP
43,550
56,761
65,421
47,177
43,364
18,467
2,957
170,960
55,270
32,823
-54,136
24,025
-69,513
-122,141
Effective Tax Rate (%)
25.68
27.56
28.11
25.71
26.44
55.13
63.52
34.8
29.08
- -
- -
126.08
- -
- -
Profit Margin (%)
4.66
5.44
5.78
3.48
2.96
1.19
0.2
9.94
3
1.58
-2.63
1.09
-2.84
-4.91
Working Capital
297,394
402,116
586,294
615,800
622,280
482,804
447,314
433,027
498,952
209,624
-151,962
106,062
-61,120
-73,840
LT Debt
61,104
52,113
124,752
251,057
450,651
414,876
469,659
218,821
434,715
483,207
251,653
432,002
583,832
608,436
Total Equity
1,099,667
1,181,067
1,307,379
1,377,011
1,439,668
1,453,117
1,506,596
1,673,501
1,910,729
1,967,044
1,881,542
1,852,175
1,763,769
1,742,400
Return on Invested Capital (%)
5.7
6
4.9
4.13
4.08
1
1.05
1.83
2.21
- -
- -
0.09
- -
- -
Return on Capital (%)
0.93
1.37
1.61
1.62
1.31
1.16
1.85
7.12
0.09
- -
- -
1.36
- -
- -
Return on Common Equity (%)
6.74
8.25
9.12
6.28
5.48
2.29
0.37
19.77
5.69
3.19
-5.37
2.44
-7.35
-13.13

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
909,464
1,007,616
1,082,732
LT Borrowings
475,510
504,166
499,107
LT Finance Leases
108,322
110,744
109,329
Preferred Equity and Hybrid Capital
1,257
1,257
1,257
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,546,885
1,563,872
1,620,582
Cash, Cash Equivalents & STI
99,283
101,928
107,815
Accounts Receivable, Net
477,924
441,056
427,977
Inventories
909,796
928,838
964,061
Total Current Liabilities
1,608,005
1,660,105
1,694,422
Payables & Accruals
- -
- -
- -
ST Debt
909,464
1,007,616
1,082,732
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.2%
1.29%
-4.77%
Free Cash Flow
37.76%
72.32%
-14.84%
Net Income, GAAP
459.64%
-181.39%
-389.34%
Sales/Revenue/Turnover
8.24%
7.47%
11.19%
Total Cash Common Dividend
6.29%
11.7%
30.57%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
469,999
559,774
609,984
565,098
2,204,855
2025
494,577
600,552
736,861
619,487
2,451,476
2026
534,771
596,272
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yong-Jun Huh
Full Time Employees
163
Sector
Health technology
Industry
Pharmaceuticals: major
Address
107, Ihyeon-Ro 30beon-Gil, Giheung-Gu Yongin-si GY South Korea 16924
IPO Date
Aug 28, 1978
Website
gccorp.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Green Cross Holdings Corporation functions as a prominent biotechnology enterprise, overseeing a portfolio of affiliates dedicated to healthcare solutions. The company provides a diverse array of biopharmaceutical products, including vital plasma-derived therapies and an extensive range of vaccines for infectious diseases like influenza, varicella, and hepatitis B. Beyond these, its offerings extend to specialized prescription medications, treatments for rare conditions such as Hunter syndrome and emerging therapies for Sanfilippo syndrome, alongside various over-the-counter health items. Actively engaged in advanced research and development, Green Cross Holdings focuses on groundbreaking areas like oncology, immunology, and innovative cell therapies. Recent strategic advancements include its expansion into the United States market with plasma products, notably with 'Aliglo' receiving regulatory approval and initiating exports in 2024, further solidified by the acquisition of US plasma collection centers to ensure a stable supply of raw materials. The company also continues to forge partnerships to accelerate the development and global reach of its cell therapy innovations. Established in 1967, Green Cross Holdings maintains its headquarters in Yongin, South Korea.